Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
LOS ANGELES, April 24, 2018 -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce it has entered into a $250,000 initial sales agreement with Vage Nigeria Ltd. (“Vage”), a brand support company specializing in product sourcing.
According to the terms of the agreement, Vage will pay a 50% deposit to ViaDerma upon completion of the registration of Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA. The registration process should be completed within 30 days. The balance of the order will be paid to ViaDerma upon delivery of the product in about 8-10 weeks.
Dr. Christopher Otiko, President of ViaDerma, stated “We are very pleased to be working together with Vage and their CEO, Kunle Craig to provide Vitastem to the people of Nigeria. This is only the first of many orders we expect to receive from Vage going forward.”
Kunle Craig, CEO of Vage Nigeria Ltd., commented, “Vitastem is a wonderful ointment that has exceeded all expectations during our testing. The feedback received and the results we have seen have so far been 100% positive. Infections have cleared up in just 3 days, and leg burns have seen significant improvement within 24 hours of application. I’ve witnessed firsthand the positive results brought upon by Vitastem in wound and skin treatment, and I have become a firm believer in this product. From what I have observed, Vitastem is a revolutionary medication.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: www.viadermalicensing.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: [email protected]
Phone: 310-374-6111
